Clinical Trial Update: NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab [Phase 2]

View source ↗

Summary

Phase 2 randomized neuroblastoma trial evaluating metaiodobenzylguanidine (MIBG) with vorinostat and dinutuximab. The study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Metaiodobenzylguanidine (metaiodobenzylguanidine)
• Vorinostat (vorinostat)
• dinutuximab (dinutuximab)

Snippet

Sponsor: New Approaches to Neuroblastoma Therapy Consortium | Conditions: Neuroblastoma | Phase 2 | Status: NOT_YET_RECRUITING